ANVS Annovis Bio, Inc.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimerís disease (AD), Parkinsonís disease (PD) and Alzheimerís in Down Syndrome (AD-DS).

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/29/2002
Outstanding shares:  8,100,570
Average volume:  275,778
Market cap:   $261,324,388
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03615A108
ISIN:        US03615A1088
Sedol:      BK74P87
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   5.21
PS ratio:   0.00
Return on equity:   -2,085.45%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy